Mark Throsby is CSO of Gadeta and serves as a non-executive member of ONA’s Supervisory Board. He obtained his PhD in Immunology from Monash University Melbourne, followed by a research fellowship at CNRS. He started his industry career at Crucell where he worked in various roles, notably as Director of Antibody Discovery. In 2008 he joined Merus and served as CSO until 2020 leading all its research activities. Dr Throsby is an expert in antibody engineering and immunology, an inventor of six drugs that have reached clinical testing, with more than a dozen granted patents and over 40 peer-reviewed publications.